Breaking News
February 25, 2018 - New staining method helps analyze 3D tissue samples using Nano-CT system
February 25, 2018 - Rare immune cell may prove to be potent weapon in fighting against cancer
February 25, 2018 - Connection between heart disease and cancer treatment
February 25, 2018 - Longer Endocrine Tx Better in Prostate Cancer
February 25, 2018 - Gene therapy restores normal blood glucose levels in mice with type 1 diabetes
February 25, 2018 - Desymmetrization paves way for new bioactive compounds
February 25, 2018 - Study finds underutilization of less expensive, post-acute care options for older adults
February 25, 2018 - UNIST researchers introduce new biosensing contact lens for diabetics
February 25, 2018 - Research consortium develops first 3D computer model of metabolic processes
February 25, 2018 - Adding hope to health messages may help promote preventative actions, researchers say
February 25, 2018 - Sudden Hearing Loss Recovery Hampered by Metabolic Syndrome
February 25, 2018 - First human trial of potentially game-changing diabetes treatment set to commence
February 25, 2018 - Child’s snacking patterns could be linked to genetics, study finds
February 25, 2018 - Patients with terminal cancer may be less competent to make big decisions
February 25, 2018 - Study highlights risks involved in short-term use of PICCs
February 25, 2018 - Study shows no increase in complications with ‘ad lib’ oral intake during labor
February 25, 2018 - Although Plaquenil (Hydroxychloroquine) Eases Rheumatoid Arthritis Pain it Won’t Help ‘Regular’ Arthritis
February 25, 2018 - Methotrexate May Help in Chronic Viral Arthritis
February 25, 2018 - Lack of guidance may delay a child’s first trip to the dentist
February 25, 2018 - Study shows cost-effectiveness of screening for fracture risk in older postmenopausal women
February 24, 2018 - Younger women with SCAD may benefit most from conservative treatment
February 24, 2018 - Blood Test for Concussion OK’d
February 24, 2018 - What are symptoms of an alcohol use disorder? – Rethinking Drinking
February 24, 2018 - Streamlined, cost-cutting post-treatment dental advice via iPad
February 24, 2018 - Researchers discover new regulator of the immune system
February 24, 2018 - Reducing red tape for traveling nurses
February 24, 2018 - Study supports benefits of meditation in control of attention and emotions
February 24, 2018 - Flu Vax Data ‘Only Tell Half the Story’
February 24, 2018 - Calculators – Rethinking Drinking – NIAAA
February 24, 2018 - From stem cells to a functional heart—the role of the Mesp1 gene
February 24, 2018 - Non-adherence to sleep apnea treatment linked to increased hospital readmissions
February 24, 2018 - Exercise-related posts influence health of social media pals
February 24, 2018 - Will Device Meetings in Europe Suffer Under New Ethics Rule?
February 24, 2018 - Nonstatin drug use increases by 124% in U.S., related expenditures triple
February 24, 2018 - Annual foot screening could help spot heart irregularities in people with diabetes
February 24, 2018 - Researchers developing rapid saliva test to detect Zika virus
February 24, 2018 - For Older Men, Even Light Exercise Helps
February 24, 2018 - Healthy Strategies to Beat Stress
February 24, 2018 - Cancer killing clue could lead to safer and more powerful immunotherapies
February 24, 2018 - Repeated sick days do not affect children’s learning ability, study shows
February 24, 2018 - New two-child policy in China could negatively affect women’s status and gender equality
February 24, 2018 - New research project to determine why mine dust-related lung diseases are on the rise
February 24, 2018 - A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology
February 24, 2018 - ClinicalTrials.gov: Child, Foster
February 24, 2018 - Study shows age doesn’t affect survival in patients with non-Hodgkin lymphoma after HCT
February 24, 2018 - Researchers explore how evolutionary processes guide pathways of cells
February 24, 2018 - Discovery may result in new medication to build stronger muscles in old age
February 24, 2018 - New study identifies possible target for treatment of dangerous allergic reactions
February 24, 2018 - Targeted vaccination can be successful in containing epidemic outbreaks
February 24, 2018 - Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
February 24, 2018 - ‘The Best Deals of Any Payer’: What We Heard This Week
February 24, 2018 - Blood and urine tests developed to indicate autism in children
February 24, 2018 - New low-cost microfluidic device brings single-cell technology to bedside
February 24, 2018 - Covestro and Pittsburgh Penguins announce multi-year unique partnership
February 24, 2018 - Children from low-income areas have poor outcomes after heart surgery, study finds
February 24, 2018 - Some genes can drive both metastasis and initial stages of tumor growth
February 24, 2018 - Visaris Americas announces installation of fully robotic Vision C digital X-ray suite at OGHS
February 24, 2018 - New discovery could accelerate clinical translation of stem cell-based therapies
February 24, 2018 - Respiratory disease patients with arthritis struggle to use complex inhalers
February 24, 2018 - FDA Alert: Labetalol Hydrochloride Injection by Hospira: Recall
February 24, 2018 - Flu, Tdap Vax Safe for Babies 6 Months Later
February 24, 2018 - Adults with autism show a diminished brain response to hearing their own name
February 24, 2018 - Study provides insight into neurobiology of dying
February 24, 2018 - Study finds tobacco smoke exposure among most adolescents in economically disadvantaged population
February 24, 2018 - U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections
February 24, 2018 - UCLA researchers use fluorescent colored proteins to trace origin of heart cells
February 24, 2018 - UC Riverside researchers discover way to halt cancer metastasis
February 24, 2018 - Home Routines Can Boost a Child’s Readiness for School
February 24, 2018 - FDA Investigating Misuse, Abuse of Gabapentinoids
February 24, 2018 - Scientists find key proteins control risk of osteoarthritis during aging
February 24, 2018 - Izon announce the launch of the qEV2 and qEV10 Exosome Isolation columns
February 24, 2018 - New CSIRO technology can create clean drinking water
February 24, 2018 - Treating sleep-disordered breathing may improve prognosis of heart failure patients
February 24, 2018 - More boys begin school a year late than girls, study finds
February 24, 2018 - Early life exposure to green space could have beneficial effects on cognitive function
February 24, 2018 - Joint Surgery: Aspirin Equals NOAC for Post-Acute VTE Prevention
February 23, 2018 - Scientists identify new marker of arthritis in mice
February 23, 2018 - Beetroot juice supplements may benefit patients with heart failure
February 23, 2018 - New study identifies novel molecular biomarkers of preeclampsia
February 23, 2018 - Researchers discover new link between gut bacteria and obesity
Death Rate Falls with Anti-TNF in Crohn’s

Death Rate Falls with Anti-TNF in Crohn’s

image_pdfDownload PDFimage_print

Action Points

  • Patients with Crohn’s disease (CD) treated with tumor necrosis factor (TNF) inhibitors had a statistically significant reduction in mortality relative to those treated with prolonged corticosteroid therapy, in a large retrospective study.
  • Note that the association of anti-TNF therapy and reduced mortality was in the same direction but not statistically significant among patients with ulcerative colitis (UC).

Patients with Crohn’s disease who were treated with tumor necrosis factor (TNF) inhibitors had a lower mortality risk than those who had prolonged corticosteroid therapy, a large retrospective cohort study found.

Among 1,879 Crohn’s patients initiating anti-TNF therapy, there was a significantly lower risk of death (OR 0.78, 95% CI 0.65-0.93) compared with risks for 7,694 patients treated with long-term steroids, according to James D. Lewis, MD, director of the Gastroenterology and Hepatology Clinical Research Program at the University of Pennsylvania in Philadelphia, and colleagues.

And while the mortality risk was numerically lower for patients with ulcerative colitis receiving anti-TNF treatment (n=459), the difference compared with steroid users (n=3,224) was not statistically significant (OR 0.87, 95% CI 0.63-1.22), the researchers reported in the American Journal of Gastroenterology.

“The reduced mortality rates among patients with Crohn’s disease was potentially a consequence of excess cardiovascular-related mortality and hip fractures and was largely limited to patients with multiple or serious comorbid conditions.”

Corticosteroids and anti-TNF therapies both are widely used in the treatment of inflammatory bowel disease, but both approaches are associated with potentially serious — and even fatal — adverse events, the team explained. Both classes of drugs are associated with serious infections and congestive heart failure, anti-TNFs have been linked with cancer, and corticosteroids are associated with pulmonary embolism and osteoporosis/fractures. Moreover, uncontrolled disease may itself raise the mortality risk.

Previous studies have demonstrated an increased mortality risk among patients with inflammatory bowel disease treated with corticosteroids, but studies assessing anti-TNF therapy have not had clear-cut results. Previous work also has not considered potentially important factors such as comorbid illness and older age in evaluating risk of death.

Lewis and colleagues therefore analyzed outcomes among patients with inflammatory bowel disease enrolled in Medicare from 2006 to 2013 and in Medicaid from 2001 to 2005.

The anti-TNF group included those who had at least one prescription for infliximab (Remicade), adalimumab (Humira), or certolizumab pegol (Cimzia) during the previous year, while the prolonged corticosteroid group included those with at least 3,000 mg prednisone or 600 mg of budesonide exposure within the past 12 months.

The primary outcome was all-cause mortality, and secondary endpoints included major adverse cardiovascular events, cancer, hip fracture, pulmonary embolism, serious infection, and emergency bowel resection. The analysis was conducted using marginal structural models and propensity scoring.

Total follow-up times among the Crohn’s disease patients were 6,222 person-years in the anti-TNF group and 24,625 person-years in the prolonged steroid group, while the corresponding numbers for ulcerative colitis were 1,213 and 9,158 person-years, respectively.

During follow-up, 1,444 patients died, with mean ages at death of 67 for patients with Crohn’s disease and 76.7 for those with ulcerative colitis.

The weighted annual incidence of death among patients with Crohn’s disease was 21.4 per 1,000 patients in the anti-TNF group and 30.1 per 1,000 in the prolonged steroid group. For ulcerative colitis, the corresponding numbers were 23 and 30.9 per 1,000, respectively.

The association between anti-TNF use and mortality risk did not differ according to age, but the lower mortality was seen only among patients with comorbidity scores higher than 3, with odds ratios of 0.65 (95% CI 0.48-0.88) for Crohn’s disease and 0.63 (95% CI 0.36-1.11) for ulcerative colitis.

For secondary endpoints among Crohn’s disease patients, anti-TNF therapy was associated with decreased risks of major adverse cardiovascular events (OR 0.68, 95% CI 0.55-0.85) and hip fracture (OR 0.54, 95% CI 0.34-0.83), although these decreased risks were not seen in patients with ulcerative colitis.

The observation that the risk of major adverse cardiovascular events was not decreased in patients with ulcerative colitis may be explained by the fact that systemic inflammation is more common in Crohn’s disease than in ulcerative colitis, the authors noted.

Hospitalizations for inflammatory bowel disease were somewhat more common in the anti-TNF group for both Crohn’s disease (OR 1.13, 95% CI 1.04-1.23) and ulcerative colitis (OR 1.53, 95% CI 1.29-1.81).

The observation that lower mortality rates seen in this analysis appeared to relate to cardiovascular disease and hip fracture as well as to the presence of serious or multiple comorbidities may have implications for treatment, the team said. Such a patient population, “which is rarely included in clinical trials and for whom some physicians may be reluctant to treat with chronic immunosuppression, may be particularly good candidates for anti-TNF agents such as corticosteroid-sparing therapy.”

Limitations of the study, the researchers said, included its residual confounding and reliance on administrative data.

The study was funded by the Patient Centered Outcomes Research Institute (PCORI).

The authors reported financial relationships with Celgene, Shire, Janssen, AbbVie, Immune Pharmaceuticals, AstraZeneca, Amgen, MedImmune, Merck, Nestle Health Science, Takeda, Pfizer, Ili Lilly, Gilead, Samsung Bioepis, Johnson & Johnson, Lycera, Evidera, GlaxoSmithKline, Janssen, Bristol-Myers Squibb, UCB, and Crescendo.

2018-01-24T14:00:00-0500

Tagged with:

About author

Related Articles